These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 32460086)

  • 1. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in MS: Initial observations from the Pacific Northwest.
    Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Guevara C; Villa E; Rosas CS; Diaz V; Naves R
    Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
    Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
    Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 will change MS care forever - No.
    Preziosa P; Rocca MA; Filippi M
    Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
    [No Abstract]   [Full Text] [Related]  

  • 6. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
    Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
    Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
    Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
    Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
    JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
    Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
    Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
    [No Abstract]   [Full Text] [Related]  

  • 18. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
    Wurm H; Attfield K; Iversen AK; Gold R; Fugger L; Haghikia A
    Mult Scler; 2020 Sep; 26(10):1261-1264. PubMed ID: 32762494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
    Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
    Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.